Skip to main content
SpringerLink
Log in

The Management of Epilepsy in the 1990s

Acquisitions, Uncertainties and Priorities for Future Research

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The pharmacological treatment of epilepsy has made considerable progress during the last decade, due to improved knowledge of the clinical pharmacology of individual drugs, acquisition of new information on the factors affecting response and need for drug treatment, and development of promising new agents. Once a clinical diagnosis of epilepsy has been made (which generally requires the occurrence of more than one seizure), treatment should be started with a single drug selected on the basis of seizure type and tolerability profile. Although there are important regional differences in prescribing patterns and individual circumstances may dictate alternative choices, carbamazepine is generally regarded as the preferred treatment for partial seizures (with or without secondary generalisation) while valproic acid (sodium valproate) is usually the first choice in most forms of generalised epilepsies.

To achieve therapeutic success, the daily dosage must be tailored to meet individual needs, and there is suggestive evidence that in some patients the dosage prescribed initially may be unnecessarily large. Plasma antiepileptic drug concentrations may aid in the individualisation of dosage, but should not be regarded as a substitute for careful monitoring of clinical response.

Although overall about 70% of patients can be completely controlled, response rate is influenced by a number of factors, the most important of which are seizure type and syndromic form. The importance of a correct syndromic classification for rational drug selection has been poorly assessed and represents a major area for future research. Patients who do not respond to the highest tolerated dose of the initially prescribed drug may be switched to monotherapy with an alternative agent or may be given add-on treatment with a second drug. Appropriate prospective trials are required to assess the merits of either strategy. If add-on therapy is selected and the patient becomes seizure free, it may be possible to discontinue the drug prescribed initially and reinstitute monotherapy. Only a minority of patients are likely to require multiple drug therapy, and it remains to be established whether specific drug combinations are more effective than others.

Until further information becomes available, the new agents should be reserved for patients failing to respond to the conventional treatments of first choice. Patients whose seizures cannot be controlled by available drugs should be reassessed, and polytherapy should be maintained only when there is clear evidence that benefits outweigh possible adverse effects. In many patients who have been seizure free for at least 2 years it may be possible to gradually discontinue all medications. The decision to withdraw treatment is determined largely by the risk of seizure relapse which, in turn, is primarily dependent on the syndromic form.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991; 41: 965–72

    PubMed  CAS  Google Scholar 

  2. Camfield P, Camfield C, Dooley JM, et al. Epilepsy after a first unprovoked seizure in childhood. Neurology 1985; 35: 1657–60

    PubMed  CAS  Google Scholar 

  3. Hirtz DG, Ellenberg JH, Nelson KB. The risk of recurrence of nonfebrile seizures in children. Neurology 1984; 34: 637–41

    PubMed  CAS  Google Scholar 

  4. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-84. Epilepsia 1993; 34: 453–68

    PubMed  CAS  Google Scholar 

  5. van den Berg BJ, Yerushalmy J. Studies on convulsive disorders in young children: I. Incidence of febrile and nonfebrile convulsions by age and other factors. Pediatr Res 1969; 3: 298–304

    Google Scholar 

  6. Annegers J, Shirts SB, Hauser WA, et al. Risk of recurrence after an initial unprovoked seizure. Epilepsia 1986; 27: 43–50

    PubMed  CAS  Google Scholar 

  7. Hopkins A, Garman A, Clarke C. The first seizure in adult life: value of clinical features, electroencephalography and computerized tomographic scaning in prediction of seizure recurrence. Lancet 1988; 1: 721–6

    PubMed  CAS  Google Scholar 

  8. Hauser WA, Rich SS, Annegers JF, et al. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990; 40: 1163–70

    PubMed  CAS  Google Scholar 

  9. Shinnar S, Berg AT, Moshe SL, et al. The risk of recurrence following a first unprovoked seizure in childhood: a prospective study. Pediatrics 1990; 85: 1076–85

    PubMed  CAS  Google Scholar 

  10. van Donselaar CA, Geerts AT, Schimsheimer RJ. Idiopathic first seizure in adult life: who should be treated?. BMJ 1991; 302: 620–3

    PubMed  Google Scholar 

  11. Boulloche I, Leloup P, Mallet E, et al. Risk of recurrence after a single unprovoked generalized tonic-clonic seizure. Dev Med Child Neurol 1989; 31: 629–32

    Google Scholar 

  12. Hart YM, Sander JWAS, Johnson AL, et al. National general practice study of epilepsy: recurrence after a first seizure. Lancet 1990; 336: 1271–4

    PubMed  CAS  Google Scholar 

  13. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–51

    PubMed  CAS  Google Scholar 

  14. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice. Epilepsia 1986; 27: 323–30

    Google Scholar 

  15. First Seizure Trial Group. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993; 43: 478–83

    Google Scholar 

  16. Camfield P, Camfield C, Dooley J, et al. A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood. Neurology 1989; 39: 851–2

    PubMed  CAS  Google Scholar 

  17. Musicco M, Beghi E, Solari A, et al. Effect of antiepileptic treatment initiated after the first unprovoked seizure on the long-term prognosis of epilepsy. Neurology 1994; 44 Suppl. 27: A337–8

    Google Scholar 

  18. Willmore LJ. Postraumatic epilepsy. Neurol Clin 1992; 10: 868–78

    Google Scholar 

  19. Yablon SA. Post-traumatic seizures. Arch Phys Med Rehab 1993; 4: 983–1001

    Google Scholar 

  20. Hauser WA. Prevention of post-traumatic epilepsy. N Engl J Med 1990: 323: 540–2

    PubMed  CAS  Google Scholar 

  21. Murri L, Parenti G, Annegers JF, editors. Pharmacological prophylaxis of post-traumatic epilepsy. Padova: Piccin Editore, 1991

    Google Scholar 

  22. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy?. Epilepsia 1981; 22: 1–10

    PubMed  CAS  Google Scholar 

  23. Beghi E, Di Mascio R, Tognoni G. Drug treatment of epilepsy. Outlines, criticism and perspectives. Drugs 1986; 31: 249–65

    CAS  Google Scholar 

  24. Smith DB, Delgado-Escueta AV, Cramer JA, et al. Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults. Neurology 1983; 33 Suppl. 1: 2–7

    PubMed  CAS  Google Scholar 

  25. Chadwick D. Standard approach to antiepileptic drug treatment in the United Kingdom. Epilepsia 1994; 35 Suppl. 4: S3–S10

    PubMed  Google Scholar 

  26. Pellock JM. Standard approach to antiepileptic drug treatment in the United States. Epilepsia 1994; 35 Suppl. 4: S11–8

    PubMed  Google Scholar 

  27. Callaghan N, O’Hare J, O’Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982; 24: 830–6

    PubMed  CAS  Google Scholar 

  28. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157–63

    PubMed  CAS  Google Scholar 

  29. Turnbull DM, Rawlins MD, Weightman D, et al. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982; 45: 55–9

    PubMed  CAS  Google Scholar 

  30. Turnbull DM, Howell D, Rawlins MD, et al. Which drug for the adult epileptic patients: phenytoin or valproate?. BMJ 1985; 290: 815–7

    PubMed  CAS  Google Scholar 

  31. Chadwick D, Turnbull DM. The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures. J Neurol Neurosurg Psychiatry 1985; 48: 1073–7

    PubMed  CAS  Google Scholar 

  32. Callaghan N, Kenny RA, O’Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639–44

    PubMed  CAS  Google Scholar 

  33. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic/clonic seizures in adults. N Engl J Med 1992; 327: 765–71

    PubMed  CAS  Google Scholar 

  34. Feksi AT, Kaamugisha J, Sander JWAS, et al. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. Lancet 1991; 337: 406–9

    PubMed  CAS  Google Scholar 

  35. Heller AJ, Stewart J, Hughes E, et al. Comparative efficacy and toxicity of phenobarbital, phenytoin, carbamazepine, and valproate in adults and children with newly diagnosed previously untreated epilepsy: a randomized long-term trial. J Neurol Neurosurg Psychiatry. In press

  36. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682–7

    PubMed  CAS  Google Scholar 

  37. Richens A, Perucca E. Clinical pharmacology and medical treatment. In: Laidlaw J, Richens A, Chadwick D. editors. A textbook of epilepsy. Edinburgh: Churchill-Livingstone, 1993: 495–559

    Google Scholar 

  38. Perucca E. The general principles of drug treatment. In: Shorvon SD, Dreifuss FE, Fish DF, et al., editors. The treatment of epilepsy. Oxford: Blackwell Scientific Publications Ltd. In press

  39. Porter RJ. How to use antiepileptic drugs. In: Levy RH, Mattson R, Meldrum B, et al., editors. Antiepileptic drugs. New York: Raven Press, 1989: 117–31

    Google Scholar 

  40. Okuma T, Kumashiro H. Natural history and prognosis of epilepsy: report of a multi-institutional study in Japan. Epilepsia 1981; 22: 35–53

    PubMed  CAS  Google Scholar 

  41. Holowach-Thurston J, Thurston DL, Hixon BB, et al. Prognosis of childhood epilepsy. Additional follow-up of 148 children 15 to 23 years after withdrawal of anticonvulsant therapy. N Engl J Med 1982; 306: 831–6

    Google Scholar 

  42. Rodin E, Klutke G, Chayasirisobohon C. Epileptic patients who are refractory to anticonvulsant medications. Neurology 1982; 32: 1382–4

    PubMed  CAS  Google Scholar 

  43. Todt H. The late prognosis of epilepsy in childhood: results of a prospective follow-up study. Epilepsia 1984; 25: 137–44

    PubMed  CAS  Google Scholar 

  44. Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia 1992; 33: 45–51

    Google Scholar 

  45. Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983; 24: 135–58

    PubMed  CAS  Google Scholar 

  46. Matsumoto A, Watanabe K, Sugiura M, et al. Long-term prognosis of convulsive disorders in the first year of life: mental and physical development and seizure persistence. Epilepsia 1983; 24: 321–9

    PubMed  CAS  Google Scholar 

  47. Viani F, Beghi E, Atza G, et al. Classifications of epileptic syndromes: advantages and limitations for evaluation of childhood epileptic syndromes in clinical practice. Epilepsia 1988; 29: 440–5

    PubMed  CAS  Google Scholar 

  48. Perucca E. Recipes for clinical practice. In: Trimble MR, editor. A re-appraisal of some new antiepileptic drugs. London: John Wiley, 1994: 145–61

    Google Scholar 

  49. Eadie MJ. Neurological diseases. In: Speight TM, editor. Avery’s drug treatment. Principles and practice of clinical pharmacology and therapeutics. Auckland: ADIS Press Limited, 1987: 1078–1136

    Google Scholar 

  50. Levy RH, Mattson R, Meldrum B, et al., editors. Antiepileptic Drugs. New York: Raven Press, 1989

    Google Scholar 

  51. Reynolds EH, Elwes RDC, Shorvon SD. Why does epilepsy become intractable?. Lancet 1983; 2: 952–4

    PubMed  CAS  Google Scholar 

  52. Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. BMJ 1977; 1: 1635–7

    PubMed  CAS  Google Scholar 

  53. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine. Individual variation in relation to seizure frequency and type. Neurology 1984; 34: 1252–5

    CAS  Google Scholar 

  54. Baruzzi A, Procaccianti G, Tinuper P, et al. Antiepileptic drug withdrawal in childhood epilepsy: preliminary results of a prospective study. In: Faienza C, Prati GL. editors. Diagnostic and therapeutic problems in pediatric epileptology. Amsterdam: Elsevier, 1988: 117–23

    Google Scholar 

  55. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital and carbamazepine. Arch Neurol 1986; 43: 263–5

    PubMed  CAS  Google Scholar 

  56. Elwes RDC, Johnson AL, Shorvon SD, et al. The prognosis for seizure control in newly diagnosed epilepsy. N Engl J Med 1984; 311: 944–7

    PubMed  CAS  Google Scholar 

  57. Elwes RDC, Johnson AL, Reynolds EH. The course of untreated epilepsy. BMJ 1988; 297: 948–50

    PubMed  CAS  Google Scholar 

  58. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969; 25: 295–330

    PubMed  CAS  Google Scholar 

  59. Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993; 34: 1007–16

    PubMed  CAS  Google Scholar 

  60. Annegers J, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729–37

    PubMed  CAS  Google Scholar 

  61. Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000. BMJ 1983; 287: 641–7

    PubMed  CAS  Google Scholar 

  62. Watts AE. The natural history of untreated epilepsy in a rural community in Africa. Epilepsia 1992; 33 (3): 464–8

    PubMed  CAS  Google Scholar 

  63. Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389–99

    Google Scholar 

  64. Shorvon SD. Chronic epilepsy. BMJ 1991; 302: 363–6

    PubMed  CAS  Google Scholar 

  65. Perucca E, Richens A. Antiepileptic drugs: clinical aspects. In: Richens A, Marks V, editors. Therapeutic drug monitoring. Edinburgh: Churchill-Livingstone, 1981: 320–48

    Google Scholar 

  66. Thompson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. Clin Pharmacokinet 1992; 23: 216–30

    Google Scholar 

  67. Chadwick DW. Overuse of monitoring of blood concentrations of antiepileptic drugs. BMJ 1987; 294: 723–4

    PubMed  CAS  Google Scholar 

  68. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961–4

    PubMed  CAS  Google Scholar 

  69. Kalviainen R, Keranen T, Riekkinen PJ. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1994; 46: 1009–24

    Google Scholar 

  70. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760–87

    PubMed  CAS  Google Scholar 

  71. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889–926

    PubMed  CAS  Google Scholar 

  72. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152–76

    PubMed  CAS  Google Scholar 

  73. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed?. JAMA 1989; 261: 3273–7

    PubMed  CAS  Google Scholar 

  74. Hakkarainen H. Carbamazepine vs diphenyl-hydantoin vs their combination in adult epilepsy. Neurology 1980; 30: 354

    Google Scholar 

  75. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797–802

    PubMed  CAS  Google Scholar 

  76. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex partial seizures. J Neurol Neurosurg Psychiatry 1982; 45: 1119–24

    PubMed  CAS  Google Scholar 

  77. Gram L, Drachmann Bentsen K, Parnas J, et al. Controlled trials in epilepsy: a review. Epilepsia 1992; 23: 491–519

    Google Scholar 

  78. Perucca E. The clinical pharmacology of new antiepileptic drugs. Pharmacol Res 1993; 28: 89–106

    PubMed  CAS  Google Scholar 

  79. Walker MC, Sander JW. Developments in antiepileptic drug therapy. Curr Opin Neurol Neurosurg 1994; 7: 131–9

    CAS  Google Scholar 

  80. Walker MC, Sander JW. Overtreatment with antiepileptic drugs: how extensive is the problem?. CNS Drugs 1994; 2: 335–40

    Google Scholar 

  81. Loscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?. Epilepsy Res 1994; 17: 95–134

    PubMed  CAS  Google Scholar 

  82. Macdonald RL, Kelly KM. Mechanism of action of new anticonvulsant drugs. In: Trimble MR, editor. A re-appraisal of some new antiepileptic drugs. London: John Wiley, 1994: 35–50

    Google Scholar 

  83. Porter RJ, Rogawsky MA. New antiepileptic drugs: from serependity to rational discovery. Epilepsia 1992; 33 Suppl. 1: S1–6

    PubMed  CAS  Google Scholar 

  84. Robinson MK, Black AB, Schapel GS, et al. Combined gammavinyl GABA (vigabatrin) and lamotrigine therapy in management of refractory epilepsy. Epilepsia 1993: 34 Suppl. 2: 109

    Google Scholar 

  85. Stolarek I, Blacklaw J, Forrest G, et al. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 921–4

    PubMed  CAS  Google Scholar 

  86. Pisani F, Di Perri R, Perucca E, et al. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 1224

    PubMed  CAS  Google Scholar 

  87. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409–27

    PubMed  CAS  Google Scholar 

  88. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873–88

    PubMed  CAS  Google Scholar 

  89. Patsalos PN, Duncan JS. New antiepileptic agents: a review of their current status and clinical potential. CNS Drugs 1994; 2: 40–77

    Google Scholar 

  90. Pellock JM. The use of new anticonvulsant drugs in children. In: Trimble MR, editor. A re-appraisal of some new antiepileptic drugs. London: John Wiley, 1994: 127–43

    Google Scholar 

  91. Pisani F, Perucca E, Avanzini G, et al. New antiepileptic drugs. Amsterdam: Elsevier, 1991: 1–196

    Google Scholar 

  92. Duncan JS. Vigabatrin. In: Trimble MR, editor. A re-appraisal of some new antiepileptic drugs. London: John Wiley, 1994: 5

    Google Scholar 

  93. Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397–400

    PubMed  CAS  Google Scholar 

  94. Leppik IE. Lamotrigine. In: Trimble MR, editor. A re-appraisal of some new antiepileptic drugs. London: John Wiley, 1994: 91–102

    Google Scholar 

  95. Editorial. Oxcarbazepine. Lancet 1989; 334: 196–8

    Google Scholar 

  96. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut Syndrome). N Engl J Med 1993; 328: 29–33

    Google Scholar 

  97. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041–65

    PubMed  CAS  Google Scholar 

  98. Appleton RE, Montiel-Viesca F. Vigabatrin in infantile spasms — why add-on?. Lancet 1992; 341: 962

    Google Scholar 

  99. Chadwick D. A practical guide to discontinuing antiepileptic drugs. CNS Drugs 1994; 2: 423–8

    Google Scholar 

  100. Pedley TA. Discontinuing antiepileptic drugs. N Engl J Med 1988; 318: 982–4

    PubMed  CAS  Google Scholar 

  101. Chadwick D, Reynolds EH. When do epileptic patients need treatment? Starting and stopping medication. BMJ 1985; 290: 1885–8

    PubMed  CAS  Google Scholar 

  102. Oller-Daurella L, Oiler LF-V. Suppression of antiepileptic treatment. Eur Neurol 1987; 27: 106–13

    PubMed  CAS  Google Scholar 

  103. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994; 44: 601–8

    PubMed  CAS  Google Scholar 

  104. Shinnar S, Vining EPG, Mellits ED, et al. Discontinuing antiepileptic medication in children with epilepsy after two years without seizures. A prospective study. N Engl J Med 1985; 313: 976–80

    CAS  Google Scholar 

  105. Callaghan N, Ganett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. N Engl J Med 1988; 318: 942–6

    PubMed  CAS  Google Scholar 

  106. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomized study of antiepileptic drug withdrawal in patients in remission. Lancet 1991; 337: 1175–80

    Google Scholar 

  107. Shinnar S, Berg AT, Moshè SL, et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol 1994; 35: 534–45

    PubMed  CAS  Google Scholar 

  108. Emerson R, D’Souza BJ, Vining EP, et al. Stopping medication in children with epilepsy. Predictors of outcome. N Engl J Med 1988; 304: 1125–9

    Google Scholar 

  109. Bouma PAD, Peters ACB, Arts RJH, et al. Discontinuation of antiepileptic therapy: a prospective study in children. J Neurol Neurosurg Psychiatry 1987; 50: 1579–83

    PubMed  CAS  Google Scholar 

  110. Tennison M, Greenwood R, Lewis D, et al. Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period. N Engl J Med 1994; 330: 1407–10

    CAS  Google Scholar 

  111. Arts WFM, Visser LH, Loonen MCB, et al. Follow-up of 146 children with epilepsy after withdrawal of antiepileptic therapy. Epilepsia 1988; 29: 244–50

    PubMed  CAS  Google Scholar 

  112. Viani F. Le epilessie nell’infanzia: diagnosi e terapia. In: Assael BM, editor. Fisiopatologia e Terapia in Pediatria. Milano: Edizioni Congress Studio, 1987: 119–37

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Ricerche Farmacologiche ‘Mario Negrt’, Via Eritrea, 62, 20157, Milano, Italy

    Ettore Beghi

  2. Epilepsy Centre and Neurological Clinic, Ospedale San Gerardo, Monza, Italy

    Ettore Beghi

  3. Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

    Emilio Perucca

Authors
  1. Ettore Beghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilio Perucca
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beghi, E., Perucca, E. The Management of Epilepsy in the 1990s. Drugs 49, 680–694 (1995). https://doi.org/10.2165/00003495-199549050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549050-00004

Keywords

Search

Navigation